The Latest Cardiac and Vascular News
PETAH TIKVA, Israel & BOCA RATON, Fla.–(BUSINESS WIRE)–Biobeat Technologies, Ltd., developer of the first FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and treatment of hypertension, announced today the closing of a $50 million Series B equity financing. The time has arrived […]
DUBLIN, Jan. 7, 2026 /PRNewswire/ — LUMA Vision Ltd., a leader in cardiac 4D navigation and imaging, today announced the successful completion of 15 VERAFEYE™-guided persistent atrial fibrillation (AF) ablation procedures conducted as part of a clinical study in collaboration with…
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter.
Abbott’s Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted…
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced the U.S. launch of the next generation LifeVest® wearable cardioverter defibrillator (WCD). This marks the fifth FDA-approved LifeVest WCD, which works seamlessly with the recently launched next generation LifeVest WCD garment, the most comfortable LifeVest […]
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to […]
ATLANTA, Dec. 18, 2025 /PRNewswire/ — Huxley Medical, Inc. announced the SANSA® home sleep apnea test has received regulatory clearance from the United States Food and Drug Administration (FDA) to be used as a diagnostic ECG monitor, making SANSA the first home sleep apnea test capable…
Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology center Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology center
MIT-alumni-founded Thermedical advances novel deep-tissue ablation technology to address critical unmet needs in severe ventricular tachycardia WESTON, Mass.–(BUSINESS WIRE)–Thermedical®, a developer of advanced thermal-ablation technologies, today announced that the first patient has been treated in a pivotal clinical study evaluating its Saline Enhanced Radiofrequency (SERF) Ablation System with the Durablate® […]
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.
